Are We Ready to Use Cost-Effectiveness Analysis in Health Care Decision-Making? A Health Services Research Challenge for Clinicians, Patients, Health Care Systems, and Public Policy

Medical Care

Volumn 36, Issue SUPPL., 1998, Pages

  Power, Elaine J ^a,b   Eisenberg, John M ^a  

^a AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

^b U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

Cost effectiveness analysis; Health policy; Health services research; Managed care

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH INSURANCE; HEALTH SERVICE; HEALTH SERVICES RESEARCH; MANAGEMENT; ORGANIZATION AND MANAGEMENT; UNITED STATES;

COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; HEALTH POLICY; HEALTH SERVICES; HEALTH SERVICES RESEARCH; MANAGED CARE PROGRAMS; POLICY MAKING; UNITED STATES;

EID: 0032065742     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005650-199805001-00002     Document Type: Article

References (28)

1. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
2. Eisenberg JM. Clinical economics: A guide to the economic analysis of clinical practices. JAMA 1989;262:2879.
3. Eddy DM. Clinical decision making: From theory to practice. Cost-effectiveness analysis. Will it be accepted? JAMA 1992;268:132.
4. Council on Ethical and Judicial Affairs, American Medical Association. Ethical issues in managed care. JAMA 1995;273:330.
5. Udvarhelyi IS, Colditz GA, Rai A, et al. Cost-effectiveness and cost-benefit analyses in the medical literature. Ann Int Med 1992;116:238.
6. Russell L, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine. JAMA 1996;276:1172.
7. Elixhauser A, Halpern M, Schmier J, Luce BR. Health care cost-benefit and cost-effectiveness analysis from 1991 to 1996: An updated bibliography. Med Care 1998;36(suppl):MS1.
8. Steiner CA, Powe NR, Anderson GF, et al. Technology coverage decisions by health care plans and considerations by medical directors. Med Care 1997;35:472.
9. Grabowski H, Mullins CD. Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions. Soc Sci Med 1997;45:535.
10. Lyles A, Luce BR, Rentz AM. Managed care pharmacy, socioeconomic assessments and drug adoption decisions. Sco Sci Med 1997;45:511.
11. Sloan F, Whetten-Goldstein K, Wilson A. Hospital pharmacy decisions, cost containment, and the use of cost-effectiveness analysis. Sco Sci Med 1997;45:523
12. US Office of Technology Assessment. Identifying Health Technologies That Work: Searching for Evidence. Washington, DC: US Government Printing Office, 1994.
13. Holohan TV. Cost-effectiveness modeling of simultaneous pancreas-kidney transplantation. Int J Tech Assess Health Care 1996;12:416.
14. Cromwell J, Bartosch WJ, Firore MC, et al. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. JAMA 1997;278:1759.
15. Rouse DJ, Andrews WW, Goldenberg RL, Owen J. Screening and treatment of asymptomatic bacteriuria of pregnancy to prevent pyelonephritis: a cost-efectiveness and cost-benefit analysis. Obstet Gynecol 1995;86:119.
16. Drummond MF, Davies L. Economic analysis alongside clinical trials: Revisiting the methodological issues. Int J Tech Assess Health Care 1991;7:561.
17. Eisenberg JM, Schulman KA, Click H, Koffer H. Pharmacoeconomics: Economic evaluation of pharmaceuticals. In: Strom BL, ed. Pharmacoepidemiology. New York: John Wiley & Sons, 1994.
18. Powe NR, Griffiths RI. Clinical-economic trials. In: US Office of Technology Assessment. Tools for evaluating health technologies: Five background papers. Washington DC: US Government Printing Office, 1995.
19. Steiner CA, Powe NR, Anderson GF, et al. The review process used by US health care plans to evaluate new medical technology for coverage. J Gen Intern Med 1996;11:294.
20. Greco PJ, Eisenberg JM. Changing physicians' practices. N Engl J Med 1993;329:1271.
21. Berger ML. Design of prospective cost-effectiveness clinical trials: The critical role of the comparator group. Drug Information Journal 1995;29:1415.
22. US Department of Health and Human Services, Health Care Financing Administration. Medicare program: Criteria and procedures for making medical services coverage decisions that relate to health care technology. Proposed rule. Federal Register 1989;54:5302.
23. Vladeck BC. Statement on Medicare coverage policy before the House Ways and Means Committee. Subcommittee on Health. Baltimore, MD: Health Care Financing Administration, April 17, 1997.
24. US Department of Health and Human Services, Centers for Disease Control and Prevention. A practical guide to prevention effectiveness: Decision and economic analyses. Atlanta, GA: CDC, 1995.
25. Luce BR, Brown RE. The use of technology assessment by hospitals, health maintenance organizations, and third-party payers in the United States. Int J Tech Assess Health Care 1995;11:79.
26. US Office of Technology Assessment. Evaluation of the Oregon Medicaid Proposal. Washington, DC: US Government Printing Office, 1992.
27. Tengs TO, Meyer G, Siegel JE, et al. Oregon's Medicaid ranking and cost-effectiveness: Is there any relationship? Med Decis Making 1996; 16:99.
28. Blumstein JF. The Oregon experiment: The role of cost-benefit analysis in the allocation of Medicaid funds. Soc Sci Med 1997;45:545.